SCHEMBL4714191

SCHEMBL4714191

CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCOC)c21

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 17/20 0.81
ROCK1 Q13464 11/20 0.81
AKT1 P31749 9/20 0.81
AKT2 P31751 9/20 0.81
AKT3 Q9Y243 9/20 0.81
DYRK1A Q13627 3/20 0.58
RPS6KA1 Q15418 3/20 0.58
ROCK2 O75116 2/20 0.58
GSK3A P49840 2/20 0.58
CDK2 P24941 2/20 0.58
DAPK3 O43293 1/20 0.58
PRKD3 O94806 1/20 0.58
PIM1 P11309 1/20 0.58
PRKACA P17612 1/20 0.58
MARK3 P27448 1/20 0.58
GRK5 P34947 1/20 0.58
CDK8 P49336 1/20 0.58
CLK2 P49760 1/20 0.58
GSK3B P49841 1/20 0.58
CDK7 P50613 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6647090 0.96 RPS6KA5 (0.79) RPS6KA5ROCK1AKT1AKT2AKT3
Gw876790X SCHEMBL4715674 0.90 RPS6KA5 (1.00) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4716856 0.86 RPS6KA5 (0.74) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4808994 0.86 RPS6KA5 (0.80) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL5467490 0.85 RPS6KA5 (0.76) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4717261 0.84 RPS6KA5 (0.68) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4808758 0.83 RPS6KA5 (0.75) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL14252545 0.83 RPS6KA5 (0.72) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL4715073 0.83 RPS6KA5 (0.71) RPS6KA5ROCK1AKT1AKT2AKT3
SCHEMBL17595570 0.83 RPS6KA5 (0.71) RPS6KA5ROCK1AKT1AKT2AKT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490367-B1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-07-23 EP disclosed
US-7348339-B2 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent GLAXO GROUP LIMITED (GB) 2008-03-25 US disclosed
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors NR4A3, XDH, MAPK8 RPS6KA5 375/4885ROCK1 846/4885AKT1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.